Charles S. Berkman

2013 - Ligand Pharmaceuticals

In 2013, Charles S. Berkman earned a total compensation of $731.8K as Vice President and General Counsel at Ligand Pharmaceuticals, a 7% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$113,340
Option Awards$277,362
Salary$283,351
Stock Awards$54,800
Other$2,908
Total$731,761

Berkman received $283.4K in salary, accounting for 39% of the total pay in 2013.

Berkman also received $113.3K in non-equity incentive plan, $277.4K in option awards, $54.8K in stock awards and $2.9K in other compensation.

Rankings

In 2013, Charles S. Berkman's compensation ranked 7,927th out of 12,286 executives tracked by ExecPay. In other words, Berkman earned more than 35.5% of executives.

ClassificationRankingPercentile
All
7,927
out of 12,286
36th
Division
Manufacturing
2,868
out of 4,612
38th
Major group
Chemicals And Allied Products
895
out of 1,466
39th
Industry group
Drugs
678
out of 1,160
42nd
Industry
Pharmaceutical Preparations
535
out of 890
40th
Source: SEC filing on April 12, 2016.

Berkman's colleagues

We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2013.

2013

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2013

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2013

Nishan de Silva

Ligand Pharmaceuticals

Chief Financial Officer

2013

John Sharp

Ligand Pharmaceuticals

Chief Financial Officer

News

You may also like